Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML) (PANTHER)SPONSOR
An Open-Label Phase 4 Study of Carfilzomib Plus Dexamethsone to Assess Tolerability and Adherence in Subjects with Relapsed or Refractory Multiple Myeloma at US Oncology Centers
A Randomized, Placebo-Controlled, Phase 3 Study to Evaluate the Ability of a Novel Genomic Biomarker to Predict Survival of Treatment Naïve, High Risk Subjects with Diffuse Large B-Cell Lymphoma Treated with R-CHOP plus Enzastaurin
An Open Label Extension Study of GBT440 Administered Orally to Patients with Sickle Cell Disease Who Have Participated in GBT440 Clinical Trials
Phase 3 clinical trial of a novel oral benzimidazole riboside in transplant recipients with cytomegalovirus (CMV) infections that are refractory to available antiviral treatment
A Phase 3, Multicenter, Randomized, Double-blind, Double-dummy, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Compared to Valganciclovir for the Treatment of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant Recipients
A Phase 1/1b First-In-Human, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549 Monotherapy and in Combination with Nivolumab in Subjects with Advanced Solid Tumors
“Relapsed Multiple Myeloma Treatment Preferences and Priorities for Patients and Caregivers in the US –A Sub-study of the CoMMpass Longitudinal Study “
A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma
Phase II, Multi-center Trial of Nivolumab and Brentuximab Vedotin in Patients with Untreated Hodgkin Lymphoma Over the Age of 60 Years or Unable to Receive Standard Adriamycin, Bleomycin, Vinblastine and Dacarbazine (ABVD) Chemotherapy
